Head-To-Head Contrast: TransMedics Group (NASDAQ:TMDX) & Advanced Biomedical Technologies (OTCMKTS:ABMT)

TransMedics Group (NASDAQ:TMDX) and Advanced Biomedical Technologies (OTCMKTS:ABMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Risk & Volatility

TransMedics Group has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.

Valuation & Earnings

This table compares TransMedics Group and Advanced Biomedical Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$441.54 million	9.11	$35.46 million	$1.36	87.48
Advanced Biomedical Technologies	$270,000.00	N/A	-$510,000.00	N/A	N/A

TransMedics Group has higher revenue and earnings than Advanced Biomedical Technologies.

Institutional & Insider Ownership

99.7% of TransMedics Group shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by company insiders. Comparatively, 34.1% of Advanced Biomedical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares TransMedics Group and Advanced Biomedical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransMedics Group	13.49%	30.50%	8.86%
Advanced Biomedical Technologies	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for TransMedics Group and Advanced Biomedical Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0	2	6	1	2.89
Advanced Biomedical Technologies	0	0	0	0	0.00

TransMedics Group presently has a consensus price target of $129.88, suggesting a potential upside of 9.17%. Given TransMedics Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe TransMedics Group is more favorable than Advanced Biomedical Technologies.

Summary

TransMedics Group beats Advanced Biomedical Technologies on 11 of the 12 factors compared between the two stocks.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About Advanced Biomedical Technologies

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.